News

The Print on MSN5d
Govt considers low-dose emicizumab for haemophilia, trial finds it more effective than existing treatment
Miracle drug’ can cost Rs 13 lakh for haemophilia A patient annually, but reduced dose found efficacious & cost-effective in ...
Stocktwits on MSN6d
Pfizer’s Hemophilia Drug Meets Goals In Late-Stage Trial In Patients With Certain Antibodies
Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and ...
Managed Healthcare Executive1d
Switching from Emicizumab to Mim8 Without a Washout Period Is Safe and Well-Tolerated in Hemophilia A Patients
A new study found that patients with hemophilia A could safely switch directly from emicizumab to Mim8 without a washout period, meaning they did not need to stop treatment before starting the new ...
Zacks Investment Research on MSN6d
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...
BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, ...
Zacks Investment Research on MSN10d
NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
Novo Nordisk NVO announced new data from the phase III FRONTIER clinical program, comprising five separate studies evaluating ...
Pfizer hemophilia therapy succeeds in late-stage trial
Pfizer (NYSE:PFE) announced Thursday that a late-stage trial for Hympavzi, its once-weekly injectable for bleeding disorder ...
InvestorsHub on MSN7d
Pfizer Reports Breakthrough Phase 3 Results for Hemophilia Therapy
Pfizer Inc. (NYSE:PFE) announced encouraging results from its Phase 3 clinical trial of HYMPAVZI, a potential new treatment ...
Clinical Trials Arena on MSN6d
Pfizer reports positive results from Phase III BAISIS trial for haemophilia
Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi (marstacimab) for adults and adolescents with haemophilia A or B with inhibitors. The ...
The American Journal of Managed Care7d
Marstacimab Improved Key Bleeding Outcomes in Hemophilia A or B
Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...
Pfizer’s HYMPAVZI Shows Superiority in Hemophilia A/B with Inhibitors in Phase 3 Study
On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...
PharmaTimes2h
First German haemophilia B patient receives gene therapy HEMGENIX
The first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at the Hemophilia Treatment Center at Hannover Medical School, CSL Behring Germany has announced.